Progresses towards safe and efficient gene therapy vectors

Show simple item record

dc.contributor.author Chira, Sergiu
dc.contributor.author Jackson, Carlo Stephan
dc.contributor.author Oprea, Iulian
dc.contributor.author Ozturk, Ferhat
dc.contributor.author Pepper, Michael Sean
dc.contributor.author Diaconu, Iulia
dc.contributor.author Braicu, Cornelia
dc.contributor.author Raduly, Lajos-Zsolt
dc.contributor.author Calin, George A.
dc.contributor.author Berindan-Neagoe, Ioana
dc.date.accessioned 2016-05-05T10:58:47Z
dc.date.available 2016-05-05T10:58:47Z
dc.date.issued 2015-09-15
dc.description.abstract The emergence of genetic engineering at the beginning of the 1970′s opened the era of biomedical technologies, which aims to improve human health using genetic manipulation techniques in a clinical context. Gene therapy represents an innovating and appealing strategy for treatment of human diseases, which utilizes vehicles or vectors for delivering therapeutic genes into the patients’ body. However, a few past unsuccessful events that negatively marked the beginning of gene therapy resulted in the need for further studies regarding the design and biology of gene therapy vectors, so that this innovating treatment approach can successfully move from bench to bedside. In this paper, we review the major gene delivery vectors and recent improvements made in their design meant to overcome the issues that commonly arise with the use of gene therapy vectors. At the end of the manuscript, we summarized the main advantages and disadvantages of common gene therapy vectors and we discuss possible future directions for potential therapeutic vectors. en_ZA
dc.description.department Immunology en_ZA
dc.description.librarian am2016 en_ZA
dc.description.sponsorship This work is part of research grant No. 128/2014; PNII- PT-PCCA-2013-4-2166 “New strategies for improving life quality and survival in cancer patients: molecular and clinical studies of the tumor genome in deuterium-depleted water treatment augmentation - GenCanD”. Dr Calin is The Alan M. Gewirtz Leukemia & Lymphoma Society Scholar. Work in Dr. Calin’s laboratory is supported in part by the NIH/NCI grants 1UH2TR00943-01 and 1 R01 CA182905-01, the UT MD Anderson Cancer Center SPORE in Melanoma grant from NCI (P50 CA093459), Aim at Melanoma Foundation and the Miriam and Jim Mulva research funds, the Brain SPORE (2P50CA127001), the Center for Radiation Oncology Research Project, the Center for Cancer Epigenetics Pilot project, a 2014 Knowledge GAP MDACC grant, a CLL Moonshot pilot project, the UT MD Anderson Cancer Center Duncan Family Institute for Cancer Prevention and Risk Assessment, a SINF grant in colon cancer, the Laura and John Arnold Foundation, the RGK Foundation and the Estate of C. G. Johnson, Jr,. en_ZA
dc.description.uri http://www.impactjournals.com/oncotarget en_ZA
dc.identifier.citation Chira, S, Jackson, CS, Oprea, I, Ozturk, F, Pepper, MS, Diaconu, I, Braicu, C, Raduly, L-Z, Calin, GA & Berindan-Neagoe, I 2015, 'Progresses towards safe and efficient gene therapy vectors', Oncotarget, vol. 6, no. 321, pp. 30675-30703. en_ZA
dc.identifier.issn 1949-2553
dc.identifier.uri http://hdl.handle.net/2263/52471
dc.language.iso en en_ZA
dc.publisher Impact Journals en_ZA
dc.rights Copyright: [Authors] et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License. en_ZA
dc.subject Biomedical technologies en_ZA
dc.subject Gene therapy en_ZA
dc.subject Human diseases en_ZA
dc.subject Patients’ body en_ZA
dc.title Progresses towards safe and efficient gene therapy vectors en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record